CSF2 and congenital rubella syndrome: In the treatment of CRS, whether through specific antibody therapy or TALEN mediated knockout of GM-CSF in CAR-T cells, the neutralization of GM-CSF is sufficient to reduce the release of inflammatory cytokines in vitro [57].